SDS Number 2925 Approved/Revised 18-Apr-2008 Version 14
DYAZIDE CAPSULES
Material
SAFETY DATA SHEET
1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE
COMPANY/UNDERTAKING
space
Material DYAZIDE CAPSULES
space
DYAZIDE CAPSULES 25 MG/37.5 MG * TRIAMTERENE AND HYDROCHLOROTHIAZIDE,
Synonym(s)
FORMULATED PRODUCT
space
GlaxoSmithKline, Corporate Environment, Health & Safety
Company Name
980 Great West Road
Brentford, Middlesex TW8 9GS UK
space
UK General Information: +44-20-8047-5000
Transport Emergency (EU) +44-1865-407333
Medical Emergency +1-612-221-3999, Ext 221
Information and Advice: US number, available 24 hours
Multi-language response
space
GlaxoSmithKline, Corporate Environment, Health & Safety
One Franklin Plaza, 200 N 16th Street
Philadelphia, PA 19102-1225 US
space
US General Information: +1-888-825-5249
Transport Emergency (non EU) +1-703-527-3887
US number, available 24 hours
Multi-language response
.
2. COMPOSITION / INFORMATION ON INGREDIENTS
space
Ingredients CAS # Percent EC-No.
HYDROCHLOROTHIAZIDE 58-93-5 16
TRIAMTERENE 396-01-0 24 206-904-3
Other components below reportable levels 60
3. HAZARDS IDENTIFICATION
space
Expected to be non-combustible.
Fire and Explosion
space
Caution - Pharmaceutical agent.
Health
Eye irritant.
Exposure might occur via ingestion; skin; eyes.
Health effects information is based on hazards of components.
space
No information is available about the potential of this product to produce adverse
Environment
environmental effects.
4. FIRST-AID MEASURES
space
Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the
Ingestion
exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the
exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
space
Physical form suggests that risk of inhalation exposure is negligible.
Inhalation
Page 1 / 5
SDS Number 2925 Approved/Revised 18-Apr-2008 Version 14
DYAZIDE CAPSULES
Material
space
Using appropriate personal protective equipment, remove contaminated clothing and flush
Skin Contact
exposed area with large amounts of water. Obtain medical attention if skin reaction occurs,
which may be immediate or delayed.
space
Wash immediately with clean and gently flowing water. Continue for at least 15 minutes.
Eye Contact
Obtain medical attention.
space
NOTES TO HEALTH PROFESSIONALS
Medical treatment in cases of overexposure should be treated as an overdose of a thiazide
Medical Treatment
diuretic. Treat according to locally accepted protocols. For additional guidance, refer to the
current prescribing information or to the local poison control information centre.
space
None for occupational exposure.
Medical Conditions
Caused or Aggravated by
Exposure
space
Pre-placement and periodic health surveillance is not usually indicated. The final
Health Surveillance
determination of the need for health surveillance should be determined by local risk
Procedures
assessment.
space
No specific antidotes are recommended.
Antidotes
.
5. FIRE-FIGHTING MEASURES
space
Not expected for the product, although the packaging is combustible.
Fire and Explosion Hazards
space
Water or foam extinguishers are recommended.
Extinguishing Media
Carbon dioxide or dry powder extinguishers may be ineffective.
space
For single units (packages): No special requirements needed.
Special Firefighting
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or
Procedures
flammable vapours might be evolved from fires involving this product and associated
packaging, self contained breathing apparatus and full protective equipment are
recommended for firefighters.
If possible, contain and collect firefighting water for later disposal.
space
Toxic, corrosive or flammable thermal decomposition products are expected when the
Hazardous Combustion
product is exposed to fire.
Products
6. ACCIDENTAL RELEASE MEASURES
space
Wear protective clothing and equipment consistent with the degree of hazard.
Personal Precautions
space
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage
Environmental Precautions
systems.
space
Collect and place it in a suitable, properly labelled container for recovery or disposal.
Clean-up Methods
space
No specific decontamination or detoxification procedures have been identified for this
Decontamination Procedures
product.
7. HANDLING AND STORAGE
space
HANDLING
Avoid breaking or crushing capsules.
General Requirements
space
No storage requirements necessary for occupational hazards. Follow product information
STORAGE
storage instructions to maintain efficacy.
Page 2 / 5
SDS Number 2925 Approved/Revised 18-Apr-2008 Version 14
DYAZIDE CAPSULES
Material
8. EXPOSURE CONTROLS / PERSONAL PROTECTION
space
TRIAMTERENE
INGREDIENT
1
GSK Occupational Hazard
Category
1000 MCG/M3 (8 HR TWA)
GSK Occupational
Exposure Limit
HYDROCHLOROTHIAZIDE
INGREDIENT
2
GSK Occupational Hazard
Category
500 MCG/M3 (8 HR TWA)
GSK Occupational
Exposure Limit
space
PERSONAL PROTECTIVE EQUIPMENT
Wear approved safety glasses with side shields if eye contact is possible.
Eye Protection
space
Follow all local regulations if personal protective equipment (PPE) is used in the workplace.
Other Equipment or
Wash hands and arms thoroughly after handling.
Procedures
9. PHYSICAL AND CHEMICAL PROPERTIES
space
Appearance
Opaque.
Clarity
space
Red/white.
Colour
space
Capsule.
Physical Form
10. STABILITY AND REACTIVITY
space
This product is expected to be stable.
Stability
space
None for normal handling of this product.
Conditions to Avoid
11. TOXICOLOGY INFORMATION
space
This product contains active ingredient(s) with the following activity: diuretic that can affect
Pharmacological Effects
the function of the kidneys.
space
No specific target organ effects have been identified.
Target Organ Effects
space
Routes of Exposure
Adverse effects might occur following ingestion.
Oral Toxicity
space
No studies have been conducted.
Inhalation Toxicity
space
Irritation is not expected following direct contact.
Skin Effects
space
Irritation might occur following direct contact with eyes.
Eye Effects
space
Sensitisation (allergic skin reaction) is not expected.
Sensitisation
space
Not expected to be genotoxic under occupational exposure conditions.
Genetic Toxicity
space
Contains a material classified as a carcinogen by external agencies. (NTP) Not expected to
Carcinogenicity
produce cancer in humans under occupational exposure conditions.
space
Not expected to produce adverse effects on fertility or development under occupational
Reproductive Effects
exposure conditions. Insufficient information available to classify this material for hazard to
milk production.
space
None known for occupational exposure.
Other Adverse Effects
12. ECOLOGICAL INFORMATION
space
This material contains two or more active pharmaceutical ingredients that have been tested,
Summary
one of which may be harmful if released directly to the environment. Specific information on
that active pharmaceutical ingredient is provided below. Appropriate precautions should be
taken to limit release of this material to the environment. Local regulations and procedures
should be consulted prior to environmental release.
Page 3 / 5
SDS Number 2925 Approved/Revised 18-Apr-2008 Version 14
DYAZIDE CAPSULES
Material
space
ECOTOXICITY
Aquatic
This material contains an active pharmaceutical ingredient that is not
Activated Sludge
toxic to activated sludge microorganisms.
Respiration
space
IC50: > 100 mg/l, 3 Hours, Activated sludge, Nominal
space
NOEC: 100 mg/l, 3 Hours, Activated sludge, Static test
space
This material contains an active pharmaceutical ingredient that is
Algal
harmful to algae.
space
IC50: 14 mg/l, 72 Hours, Selenastrum capricornutum,
green algae, Measured
space
NOEC: 5 mg/l, 72 Hours, Selenastrum capricornutum,
green algae, Static test
space
No toxicity to daphnids was observed for the active pharmaceutical
Daphnid
ingredient in this mixture, but the upper range of the test was limited
by the low water solubility of this compound. This material contains an
active pharmaceutical ingredient that is not harmful to daphnids in
chronic toxicity studies.
space
EC50: > 10 mg/l, 48 Hours, Daphnia magna,
Measured
space
NOEC: 10 mg/l, 48 Hours, Daphnia magna, Static test
space
Chronic LOEC: > 10 mg/l, 7 Days, Ceriodaphnia dubia, Nominal
space
Chronic NOEC: 10 mg/l
space
No toxicity to fish was observed for the active pharmaceutical
Fish
ingredient, but the upper range of the test was limited by the low water
solubility of the compound.
space
Adult Oncorhyncus mykiss, rainbow trout
space
EC50: > 13 mg/l, 96 Hours, Measured
space
Adult Oncorhyncus mykiss, rainbow trout
space
NOEC: 13 mg/l, 96 Hours, Static test
space
MOBILITY
This material contains an active pharmaceutical ingredient that for environmental fate
Solubility
predictions has limited solubility in water.
space
This material contains an active pharmaceutical ingredient that will not readily enter into air
Volatility
from water.
space
Henrys Law Constant < 1.90E-15 atm m3/mol, Estimated at 25 C
space
This material contains an active pharmaceutical ingredient that is not likely to adsorb to soil
Adsorption
or sediment if released directly to the environment. This material contains an active
pharmaceutical ingredient that is not likely to adsorb to sludge or biomass if released directly
to the environment.
space
Sludge Biomass 1.95 Measured at pH 7
Distribution Coefficient
(log Kd):
space
This material contains an active pharmaceutical ingredient with octanol/water partition
Partitioning
coefficient data that suggests that for environmental fate predictions the active
pharmaceutical ingredient will not have the tendency to distribute into fats.
space
PERSISTENCE/DEGRADATION
This material contains an active pharmaceutical ingredient that is likely to undergo
Photolysis
photodegradation.
space
UV/Visible Spectrum: 356 nm , Measured
space
This material contains an active pharmaceutical ingredient that is not readily biodegradable
Biodegradation
but is inherently biodegradable (as defined by 1993 OECD Testing Guidelines) and is not
expected to persist in the environment.
space
Aerobic - Inherent
Percent Degradation: 50 %, 14 days, Modified Zahn-Wellens, primary biodegradation,
loss of parent., Activated sludge
Page 4 / 5
SDS Number 2925 Approved/Revised 18-Apr-2008 Version 14
DYAZIDE CAPSULES
Material
space
This material contains an active pharmaceutical ingredient that will not have a tendency to
Bioaccumulation
bioaccumulate in the food chain.
13. DISPOSAL CONSIDERATIONS
space
Collect for recycling or recovery if possible. The disposal method for rejected
Disposal Recommendations
products/returned goods must ensure that they cannot be re-sold or re-used.
space
Observe all local and national regulations when disposing of this product.
Regulatory Requirements
14. TRANSPORT INFORMATION
space
The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons
trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous
goods for transport.
space
UN Classification and Labelling
Transportation and shipping of this product is not restricted. It has no known,
Transport Information
significant hazards requiring special packaging or labelling for air, maritime, US or
European ground transport purposes.
15. REGULATORY INFORMATION
space
The information included below is an overview of the major regulatory requirements. It should not be considered to be an
exhaustive summary. Local regulations should be consulted for additional requirements.
space
EU Classification and Labelling
Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product,
cosmetic product or medical device.
space
US OSHA Standard (29 CFR Part 1910.1200)
This dosage form is exempt from the requirements of the OSHA Hazard Communication
Classification
Standard.
space
Other US Regulations
Exempt
TSCA Status
16. OTHER INFORMATION
space
GSK Hazard Determination
References
space
14
SDS Version Number
space
SDS Sections Updated
Sections Subsections
COMPOSITION / INFORMATION ON INGREDIENTS
space
The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of
issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine
the applicability of this information and the suitability of the material or product for any particular purpose.
Page 5 / 5
|